(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT – Charles Ryan
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the…
